Satsuma Pharmaceuticals to Present at the 31st Annual Oppenheimer Healthcare Conference
Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) announced its participation in the 31st Annual Oppenheimer Healthcare Conference on March 16, 2021, at 3:10 PM Eastern Time.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) announced its participation in the 31st Annual Oppenheimer Healthcare Conference on March 16, 2021, at 3:10 PM Eastern Time. The conference will be held virtually from March 16 to 18, with a live webcast available for following the presentation. Satsuma is focused on developing STS101, a novel treatment for acute migraine, utilizing a proprietary dry-powder formulation of dihydroergotamine mesylate (DHE) that simplifies self-administration. The company aims to enhance the clinical effectiveness of DHE while addressing limitations of existing treatments.
Details
News Market Reaction – STSA
The recorded move for STSA in the trading session of this news was +1.68%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., March 10, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that management will present a corporate overview at the 31st Annual Oppenheimer Healthcare Conference on March 16, 2021 at 3:10 PM Eastern Time. The conference will be held virtually with participants joining remotely from March 16th to the 18th.
A webcast of the presentation can be followed live online via the link below: https://wsw.com/webcast/oppenheimer9/stsa/2746007 or please visit the “Events and Presentations” page within the “Investors” section of the Satsuma Pharmaceuticals website at www.satsumarx.com.
If you are interested in arranging a one-on-one meeting, please contact your Oppenheimer & Co. Inc. representative or contact Corey Davis at LifeSci Advisors.
About Satsuma Pharmaceuticals and STS101
Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic product candidate for the acute treatment of migraine. Its product candidate, STS101, is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, or DHE, which is designed to be quickly and easily self-administered with a proprietary pre-filled, single-use, nasal delivery device. DHE products have long been recommended as a first-line therapeutic option for the acute treatment of migraine and have significant advantages over other therapeutics for many patients. However, broad use has been limited by invasive and burdensome administration and/or sub-optimal clinical performance of available injectable and liquid nasal spray products. STS101 is in Phase 3 development and specifically designed to deliver the clinical advantages of DHE while overcoming these shortcomings.
Satsuma is headquartered in South San Francisco, California with operations in both California and Research Triangle Park, North Carolina. For further information, please visit www.satsumarx.com.
INVESTOR AND CORPORATE CONTACTS:
Corey Davis, PhD
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com
Tom O’Neil, Chief Financial Officer
Satsuma Pharmaceuticals, Inc.
tom@satsumarx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.